NCT04197310: Cabozantinib and Nivolumab for Carcinoid Tumors

NCT04197310
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known brain metastases; Patients who have received prior cabozantinib or prior therapy with an anti-PD-1, anti-PD-L1/2, anti-CD137, or anti-CTLA-4 antibody (e.g. nivolumab, pembrolizumab, ipilimumab, etc.); Patients who have not received at least one line of therapy
https://ClinicalTrials.gov/show/NCT04197310

Comments are closed.

Up ↑